Tereza Vaclova

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations.

Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 23, 2023

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.

Journal: Scientific reports
Published: October 11, 2021

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.

Journal: Nature communications
Published: June 17, 2020

Genetic variation in the NEIL2 DNA glycosylase gene is associated with oxidative DNA damage in BRCA2 mutation carriers.

Genetic variation in the NEIL2 DNA glycosylase gene is associated with oxidative DNA damage in BRCA2 mutation carriers.

Journal: Oncotarget
Published: March 28, 2017

Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.

Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.

Journal: Human molecular genetics
Published: August 04, 2016

Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.

Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.

Journal: Oncotarget
Published: January 28, 2016

Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance.

Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance.

Journal: NPJ genomic medicine
Published: January 01, 2016

DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers.

DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers.

Journal: Breast cancer research and treatment
Published: February 17, 2015

DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers.

DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers.

Journal: PLoS genetics
Published: October 23, 2013
Showing 1-9 of 9

Last Updated: 09/26/2026